The global TAM for treatment of diabetes is massive. US equity markets have a lot of experience valuing continuous glucose monitoring (CGM) device makers such as the market leader, Dexcom (NYSE; DXCM);
- The global TAM for CGM device makers is c. US$5bn with cagr c.11%.
- DXCM current mkt value = US$35bn, equating to a revenue multiple of about x35!!!
- The point is, US equity markets go bananas over diabetes treatment innovation due to huge TAM, cagr and IP protection.
For the treatment of DFU's;
- TAM of US$7bn and likely c.10% cagr
- The application of Synpath to DFU's is a sleeping giant under the sp of PNV.
- Forums
- ASX - By Stock
- Ann: First Patient enrolled - SynPath Diabetic Foot Ulcer Trial
The global TAM for treatment of diabetes is massive. US equity...
Featured News
Add PNV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.08 |
Change
0.050(2.46%) |
Mkt cap ! $1.435B |
Open | High | Low | Value | Volume |
$2.01 | $2.09 | $2.01 | $3.563M | 1.737M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3195 | $2.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.09 | 12574 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 13193 | 2.060 |
7 | 45683 | 2.050 |
5 | 56513 | 2.040 |
2 | 11513 | 2.030 |
1 | 2771 | 2.020 |
Price($) | Vol. | No. |
---|---|---|
2.090 | 8692 | 2 |
2.100 | 46739 | 8 |
2.110 | 11513 | 2 |
2.120 | 18513 | 3 |
2.130 | 16730 | 3 |
Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
Last
$2.07 |
  |
Change
0.050 ( 1.95 %) |
|||
Open | High | Low | Volume | ||
$2.01 | $2.09 | $2.01 | 315933 | ||
Last updated 15.59pm 24/05/2024 ? |
Featured News
PNV (ASX) Chart |